Views: 1,474 | Downloads:
20
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
An Open, Non Comparative Study of Ofloxacin I.V. on the Treatment of Acute Symptomatic Urinary Tract Infection
Asvanich K 
,
Fugpholngam V ,
Srimuang S ,
Tanphaichitra D
,
Fugpholngam V ,
Srimuang S ,
Tanphaichitra D The clinical efficacy and the safety of ofloxacin LV. in 35 acute symptomatic urinary tract
patients were evaluated. The drug was intravenously administered, 400 mg starting dose then
200 mg once-daily for 3-5 days. The therapeutic success rate and eradication rate in UTI case
were 100 per cent in all cases when evaluated immediately after completion of drug treatment,
therapeutic success rate and eradication rate at the follow-up evaluation were 97.2 per cent and
91.6 per cent respectively. Also, 5 cases of acute bronchitis and 2 salmonellosis were also
administered intravenously, 400 mg once-daily dose and 400 mg twice daily dose respectively.
No serious side effects of ofloxacin LV. therapy were observed in any of our patients.
Key word : Ofloxacin, UTI, Bronchitis, Salmonellosis
ASV ANICH K, et al
J Med Assoc: Thai 2000; 83: 771-775
Ofloxacin is a broad spectrum fluoroquino-
lone agent which acts by inhibiting bacterial DNA
gyrase, with an excellent penetration into various
tissues, has very good tolerability and an extended
serum elimination half-life( l-5). Ofloxacin, one of
the most commonly prescribed fluoroquinolone
antibacterials, is active in a range of infections, and
a very effective drug for the treatment of acute
*
Department of Family Medicine,
**
Research Center,
infection caused mainly by gram-negative orga-
nisms such as enterobacteriaceae,
Haemophilus
and
Neisseria
spp(6-l0). Ofloxacin is usually adminis-
tered twice daily either orally or intravenously.
Recently a few trials in which ofloxacin was admi-
nistered once daily have been reported( ll-15). In our
study, patients who were suffering from acute symp-
tomatic UTI, received 400 mg ofloxacin LV. start-
***
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
772
K.
patients were evaluated. The drug was intravenously administered, 400 mg starting dose then
200 mg once-daily for 3-5 days. The therapeutic success rate and eradication rate in UTI case
were 100 per cent in all cases when evaluated immediately after completion of drug treatment,
therapeutic success rate and eradication rate at the follow-up evaluation were 97.2 per cent and
91.6 per cent respectively. Also, 5 cases of acute bronchitis and 2 salmonellosis were also
administered intravenously, 400 mg once-daily dose and 400 mg twice daily dose respectively.
No serious side effects of ofloxacin LV. therapy were observed in any of our patients.
Key word : Ofloxacin, UTI, Bronchitis, Salmonellosis
ASV ANICH K, et al
J Med Assoc: Thai 2000; 83: 771-775
Ofloxacin is a broad spectrum fluoroquino-
lone agent which acts by inhibiting bacterial DNA
gyrase, with an excellent penetration into various
tissues, has very good tolerability and an extended
serum elimination half-life( l-5). Ofloxacin, one of
the most commonly prescribed fluoroquinolone
antibacterials, is active in a range of infections, and
a very effective drug for the treatment of acute
*
Department of Family Medicine,
**
Research Center,
infection caused mainly by gram-negative orga-
nisms such as enterobacteriaceae,
Haemophilus
and
Neisseria
spp(6-l0). Ofloxacin is usually adminis-
tered twice daily either orally or intravenously.
Recently a few trials in which ofloxacin was admi-
nistered once daily have been reported( ll-15). In our
study, patients who were suffering from acute symp-
tomatic UTI, received 400 mg ofloxacin LV. start-
***
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
772
K.
Download:
PDF